SB 204990

SB 204990 is a cell-permeable prodrug form of SB 201076, an inhibitor of ATP citrate lyase. SB 204990 inhibits fatty acid and cholesterol synthesis in HepG2 cells in a concentration-dependent manner. Oral administration of SB 204990 (25 mg/kg) reduces plasma levels of the lipoproteins VLDL, LDL, and HDL by 21, 40, and 22%, respectively, in dogs. It also reduces VLDL synthesis and plasma cholesterol and triglyceride levels in rats in a dose-dependent manner.Formal Name: (3R,5S)-rel-5-[6-(2,4-dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid. CAS Number: 154566-12-8. Molecular Formula: C18H22Cl2O5. Formula Weight: 389.3. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMF:PBS(pH7.2) (1:2): 0.33 mg/ml, DMSO: 20 mg/ml, Ethanol: 1 mg/ml. lambdamax: 219 nm. SMILES: O=C1[C@](CC(O)=O)(O)C[C@@H](CCCCCCC2=CC=C(Cl)C=C2Cl)O1. InChi Code: InChI=1S/C18H22Cl2O5/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14-10-18(24,11-16(21)22)17(23)25-14/h7-9,14,24H,1-6,10-11H2,(H,21,22)/t14-,18+/m1/s1. InChi Key: YTRNLFYTHYWDAU-KDOFPFPSSA-N.